Currently out of the existing stock ratings of John Wilkin, 9 are a BUY (100%).

John Wilkin

Work Performance Price Targets & Ratings Chart

Analyst John Wilkin, currently employed at CRAIG HALLUM, carries an average stock price target met ratio of 60% that have a potential upside of 33.53% achieved within 95 days.

John Wilkin’s has documented 18 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MYGN, Myriad Genetics.

Wall Street Analyst John Wilkin

Analyst best performing recommendations are on PSNL (PERSONALIS).
The best stock recommendation documented was for PSNL (PERSONALIS) at 8/11/2025. The price target of $7 was fulfilled within 53 days with a profit of $2.5 (55.56%) receiving and performance score of 10.48.

Average potential price target upside

ADPT Adaptive Biotechnologies Corp MYGN Myriad Genetics PSNL Personalis VCYT Veracyte XGN Exagen

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 30-Sep-2025

$32

$3.65 (12.87%)

$25

Buy Since 07-Oct-2020

$34

$5.65 (19.93%)

$25

11 days ago
(22-Sep-2026)

16/21 (76.19%)

$5.94 (21.17%)

163

Buy Since 08-May-2023

$27.5

$-0.85 (-3.00%)

$20

1 months 29 days ago
(04-Aug-2026)

17/17 (100%)

$2.95 (12.02%)

317

Hold Since 09-Sep-2020

$22

$-6.35 (-22.40%)

$20

2 months 3 days ago
(30-Jul-2026)

13/19 (68.42%)

$-2.18 (-9.02%)

469

Buy Since 06-Aug-2025

$28

$-0.35 (-1.23%)

$21

2 months 3 days ago
(30-Jul-2026)

3/3 (100%)

$3.82 (15.80%)

56

Show more analysts

Please expand the browser size to see the chart

Which stock is John Wilkin most bullish on?

Potential upside of $3.46 has been obtained for MYGN (MYRIAD GENETICS)

What Year was the first public recommendation made by John Wilkin?

On 2025
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?